- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Burlingame Today
By the People, for the People
Hematopoietic Stem Cell Transplantation (HSCT) Market Booming with Rapid Growth Through 2033
The global HSCT market is expected to reach $7.48 billion by 2032, driven by rising demand and technological advancements.
Feb. 3, 2026 at 4:47am
Got story updates? Submit your updates here. ›
The latest report by Coherent Market Insights indicates strong growth potential for the Hematopoietic stem cell transplantation (HSCT) market from 2026 to 2033, supported by rising industry demand, expanding applications, and ongoing technological advancements. The study delivers a clear overview of market size, revenue trends, and key growth factors shaping the global landscape.
Why it matters
HSCT is a critical treatment for various blood and bone marrow cancers, as well as other serious conditions. The rapid growth of this market highlights the increasing importance of these life-saving therapies and the need for continued innovation and investment in this field.
The details
The HSCT market is projected to grow from an estimated $3.56 billion in 2025 to $7.48 billion by 2032, driven by rising demand, expanding applications, and ongoing technological advancements. Key players in the market include Pluristem Therapeutics, CellGenix GmbH, Regen Biopharma, Lonza Group, and Kiadis Pharma, among others.
- The HSCT market is expected to expand steadily from 2026 to 2033.
- In 2025, the market is estimated to be valued at $3.56 billion.
- By 2032, the market is projected to reach $7.48 billion.
The players
Pluristem Therapeutics Inc.
A leading developer of placenta-based cell therapy products for the treatment of a variety of inflammatory and ischemic conditions.
CellGenix GmbH
A global provider of high-quality cell culture media and reagents for the cell and gene therapy industry.
Regen Biopharma Inc.
A biotechnology company focused on the development of novel stem cell therapies and immunotherapies.
Lonza Group
A leading global life sciences company that provides products and services to the pharmaceutical, biotech, and specialty ingredients markets.
Kiadis Pharma
A clinical-stage biopharmaceutical company developing innovative cell-based medicines for the treatment of life-threatening diseases.
The takeaway
The booming HSCT market reflects the critical role these therapies play in treating a wide range of serious medical conditions. As the demand for HSCT continues to grow, it will be important for companies in this space to stay at the forefront of innovation and ensure these treatments remain accessible to those who need them.
